HHS moved to allow compounding pharmacies to manufacture six specific peptide products for “wellness” use via enforcement discretion, while the FDA continues rulemaking on whether compounding should be permitted. The policy expands access for certain multi-peptide mixtures if peptides are produced by registered manufacturers and dispensed with a prescription, according to HHS documentation. The agency acknowledged that compounded peptides carry safety and efficacy risks due to a regulatory gap versus FDA-approved drugs. This shift matters for biotech-adjacent supply chains and clinicians because it changes how quickly unapproved peptide combinations can reach patients through licensed channels while enforcement remains deferred.